# Indocyanine Green for Central Nervous System Tumors

> **NCT02710240** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 336 (actual)

## Conditions studied

- Suspected Central Nervous System Tumors

## Interventions

- **DRUG:** Indocyanine Green (ICG)
- **RADIATION:** Intraoperative near-infrared (NIR)

## Key facts

- **NCT ID:** NCT02710240
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-10
- **Primary completion:** 2020-02-04
- **Final completion:** 2020-04-02
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710240, "Indocyanine Green for Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02710240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*